News

Show
news from

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Achilles to present at upcoming conferences

Load more

Search